139 related articles for article (PubMed ID: 26703895)
1. Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.
Ishibashi T; Yaguchi A; Terada K; Ueno-Yokohata H; Tomita O; Iijima K; Kobayashi K; Okita H; Fujimura J; Ohki K; Shimizu T; Kiyokawa N
Exp Hematol; 2016 Mar; 44(3):177-88.e5. PubMed ID: 26703895
[TBL] [Abstract][Full Text] [Related]
2. Acute Lymphoblastic Leukemia Patient with Variant ATF7IP/PDGFRB Fusion and Favorable Response to Tyrosine Kinase Inhibitor Treatment: A Case Report.
Zhang G; Zhang Y; Wu J; Chen Y; Ma Z
Am J Case Rep; 2017 Nov; 18():1204-1208. PubMed ID: 29133777
[TBL] [Abstract][Full Text] [Related]
3. ATF7IP as a novel PDGFRB fusion partner in acute lymphoblastic leukaemia in children.
Kobayashi K; Mitsui K; Ichikawa H; Nakabayashi K; Matsuoka M; Kojima Y; Takahashi H; Iijima K; Ootsubo K; Oboki K; Okita H; Yasuda K; Sakamoto H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Ohara A
Br J Haematol; 2014 Jun; 165(6):836-41. PubMed ID: 24628626
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.
Tomita O; Iijima K; Ishibashi T; Osumi T; Kobayashi K; Okita H; Saito M; Mori T; Shimizu T; Kiyokawa N
Leuk Res; 2014 Mar; 38(3):361-70. PubMed ID: 24367893
[TBL] [Abstract][Full Text] [Related]
5. The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL.
Xu GF; Zeng Z; Zhang ZB; Zhang XM; Wang M; Xiao Q; Li J; Xie XQ; He S; Fu HH; Liu Y; Yang ZL; Chen Y; Shi J; Wang B; Qiu HY; Zhou Q; Liu Y; Chen SN
J Cell Mol Med; 2024 Feb; 28(3):e18114. PubMed ID: 38323741
[TBL] [Abstract][Full Text] [Related]
6. EBF1-PDGFRB fusion in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications.
Schwab C; Ryan SL; Chilton L; Elliott A; Murray J; Richardson S; Wragg C; Moppett J; Cummins M; Tunstall O; Parker CA; Saha V; Goulden N; Vora A; Moorman AV; Harrison CJ
Blood; 2016 May; 127(18):2214-8. PubMed ID: 26872634
[TBL] [Abstract][Full Text] [Related]
7. Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.
Cain JA; Xiang Z; O'Neal J; Kreisel F; Colson A; Luo H; Hennighausen L; Tomasson MH
Blood; 2007 May; 109(9):3906-14. PubMed ID: 17218386
[TBL] [Abstract][Full Text] [Related]
8. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
[TBL] [Abstract][Full Text] [Related]
9. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
10. B-Cell Precursor-Acute Lymphoblastic Leukemia With EBF1-PDGFRB Fusion Treated With Hematopoietic Stem Cell Transplantation and Imatinib: A Case Report and Literature Review.
Sakurai Y; Sarashina T; Toriumi N; Hatakeyama N; Kanayama T; Imamura T; Osumi T; Ohki K; Kiyokawa N; Azuma H
J Pediatr Hematol Oncol; 2021 Jan; 43(1):e105-e108. PubMed ID: 32068648
[TBL] [Abstract][Full Text] [Related]
11. A novel subclonal rearrangement of the STRN3::PDGFRB gene in de novo acute myeloid leukemia with NPM1 mutation and its leukemogenic effects.
Wang Z; Liu T; Liu W; Gao X; Wan L; Qiu S; Song Y; Gu R; Tian Z; Wang M; Wang J; Mi Y; Wei S
Cancer Gene Ther; 2023 Nov; 30(11):1471-1484. PubMed ID: 37550570
[TBL] [Abstract][Full Text] [Related]
12. Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript.
Masuzawa A; Kiyotani C; Osumi T; Shioda Y; Iijima K; Tomita O; Nakabayashi K; Oboki K; Yasuda K; Sakamoto H; Ichikawa H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Mori T
Eur J Haematol; 2014 Mar; 92(3):263-7. PubMed ID: 24215620
[TBL] [Abstract][Full Text] [Related]
13. TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation.
Kobayashi K; Miyagawa N; Mitsui K; Matsuoka M; Kojima Y; Takahashi H; Ootsubo K; Nagai J; Ueno H; Ishibashi T; Sultana S; Okada Y; Akimoto S; Okita H; Matsumoto K; Goto H; Kiyokawa N; Ohara A
Pediatr Blood Cancer; 2015 Jun; 62(6):1058-60. PubMed ID: 25400122
[TBL] [Abstract][Full Text] [Related]
14. ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.
Uemura S; Nishimura N; Hasegawa D; Shono A; Sakaguchi K; Matsumoto H; Nakamachi Y; Saegusa J; Yokoi T; Tahara T; Tamura A; Yamamoto N; Saito A; Kozaki A; Kishimoto K; Ishida T; Nino N; Takafuji S; Mori T; Iijima K; Kosaka Y
Int J Hematol; 2018 May; 107(5):604-609. PubMed ID: 29177615
[TBL] [Abstract][Full Text] [Related]
15. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta.
Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM
N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases.
De Keersmaecker K; Versele M; Cools J; Superti-Furga G; Hantschel O
Leukemia; 2008 Dec; 22(12):2208-16. PubMed ID: 18784740
[TBL] [Abstract][Full Text] [Related]
17.
Zhang Y; Gao Y; Zhang H; Zhang J; He F; Hnízda A; Qian M; Liu X; Gocho Y; Pui CH; Cheng T; Wang Q; Yang JJ; Zhu X; Liu X
Blood; 2018 May; 131(20):2256-2261. PubMed ID: 29434033
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.
Jiang J; Greulich H; Jänne PA; Sellers WR; Meyerson M; Griffin JD
Cancer Res; 2005 Oct; 65(19):8968-74. PubMed ID: 16204070
[TBL] [Abstract][Full Text] [Related]
19. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
Roberts KG; Li Y; Payne-Turner D; Harvey RC; Yang YL; Pei D; McCastlain K; Ding L; Lu C; Song G; Ma J; Becksfort J; Rusch M; Chen SC; Easton J; Cheng J; Boggs K; Santiago-Morales N; Iacobucci I; Fulton RS; Wen J; Valentine M; Cheng C; Paugh SW; Devidas M; Chen IM; Reshmi S; Smith A; Hedlund E; Gupta P; Nagahawatte P; Wu G; Chen X; Yergeau D; Vadodaria B; Mulder H; Winick NJ; Larsen EC; Carroll WL; Heerema NA; Carroll AJ; Grayson G; Tasian SK; Moore AS; Keller F; Frei-Jones M; Whitlock JA; Raetz EA; White DL; Hughes TP; Guidry Auvil JM; Smith MA; Marcucci G; Bloomfield CD; Mrózek K; Kohlschmidt J; Stock W; Kornblau SM; Konopleva M; Paietta E; Pui CH; Jeha S; Relling MV; Evans WE; Gerhard DS; Gastier-Foster JM; Mardis E; Wilson RK; Loh ML; Downing JR; Hunger SP; Willman CL; Zhang J; Mullighan CG
N Engl J Med; 2014 Sep; 371(11):1005-15. PubMed ID: 25207766
[TBL] [Abstract][Full Text] [Related]
20. Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion.
Lengline E; Beldjord K; Dombret H; Soulier J; Boissel N; Clappier E
Haematologica; 2013 Nov; 98(11):e146-8. PubMed ID: 24186319
[No Abstract] [Full Text] [Related]
[Next] [New Search]
